There is ample literature about the health benefits of CBD for humans and animals. Many people are uncertain of its effectiveness and reporting inconsistent responses. Many question why it seems effective for some and not themselves. The answer lies in biochemistry and is the reason for the creation of the patented Higher Compound composition.
When integrative practitioner and biochemist Kevin Meehan became intrigued with the problem, he combined his knowledge and experience with his research of the Endocannabinoid system to understand where the inconsistencies lay. He recognized from scientific literature that there is an inborn error on the 6th transmembrane of the Mu opioid receptor site which affects us all in varying degrees. It's what gives opioids and cannabinoids their variances in tolerance and effectiveness and possibly gives opioids their addictive nature. He then set out to develop a natural protocol to help "level the playing field" biochemically speaking. This resulted in the creation of the Higher Compound formulas which target the optimization of the Mu and Delta Opioid receptors to help increase the effectiveness of any cannabinoid or opioid medication.
What is nanoCBD?
The overwhelmingly positive feedback we have received made it a natural decision for us to combine Higher Compound with a high quality CBD component. After an extensive search, we found an organically farmed hemp extract which has undergone a nanoemulsion process that makes the CBD water-soluble and dramatically increases its bioavailability- up to six times more bioavailable to a body!
With the combination of our patented formula and superior bioavailability of nanoCBD, Meehan Formulations is proud to offer the Higher Compound Plus formulas for an enhanced CBD experience.
Watch and Learn
CBD Nano-emulsions 101: information from 5280 Nano Technologies
Nano CBD Emulsions, often marketed as “Water Soluble CBD” are created when CBD oil is processed through highly specialized Nano-Emulsification Systems. This process decreases the size of particles small enough they can be absorbed directly into the body at a cellular level in the small intestine, thus dramatically increasing the absorption into the body and making it the most effective way to use and benefit from CBD.
The human body is made up of water. On average, the body of an adult human being contains 60% water. Most of the water in the human body is contained inside our cells. Water and Oil do not mix well. Oil and water don’t mix because water molecules are more attracted to each other than to oil molecules. Molecules of water are strongly attracted to each other because they are polar. Oil and water molecules are not attracted to each other because oil molecules are non-polar and hydrophobic or ‘water-fearing’.
The Problem with Oil
With most oil based consumer products, only about 10% of the particles get used by your body. That’s because a cell cannot fully absorb a particle that is bigger than it. Cannabinoid particles measure about 2,000 nanometers (or millionths of a meter). Human cells can only directly absorb particles that measure 10~80 nanometers.
The Solution: Nano-Emulsified CBD
Nano-emulsification makes CBD particles small enough for your body to fully utilize them and reap the benefits. Because oil and water do not mix it is essential for CBD particles to be processed and reduced to a size they can be absorbed at a cellular level.
The pharmaceutical and cosmetics industries have been using this technique to overcome this same challenge for decades. In the near future we predict that almost all cannabinoid-based products will be processed with Nano Emulsification equipment, the benefits are just so superior to traditional oil it’s not even funny.
Why would you take a supplement where 90% is wasted and not even absorbed, when you could take a supplement where 90% is absorbed.
The Process and Technology
Using High Power Ultrasonic Nano emulsification equipment, liquids are passed through high-intensity ultrasound which creates ultrasonic cavitation. This produces asymmetrically imploding bubbles and causes micro-jets that create mechanical shear forces. Ultrasonic amplitudes on the order of at least 70 microns peak-to-peak are necessary for this process to be effective. High-gain acoustic sonotrodes amplify the vibration generated by transducers to deliver the ultrasonic energy to create emulsions this allows the creation of nano-particles which cross the blood-brain barrier where traditional oil cant because they are too large.
The directive of this formulated compound is to increase the activity of the naturally occurring peptides, known as enkephalins, which are found in mammals. These peptides are known to have potent painkilling properties.
This composition does so by specifically targeting the two opioid receptor sites (MU and Delta) which modulate enkephalins. In doing so, the potential of increasing the biochemical influence of the CBD/ THC components can be demonstrably enhanced. The use of both CBD and
THC for pain killing purposes has been well documented.
This formula may also enhance enkephalins as an isolated component without exhibiting any substantial psychoactive enhancing effects.
Thus far, this composition has been reported in those who have used it to reduce pain, lower anxiety, improve mood, and mitigate tremors. More research will be conducted based on these promising results.
This formulation is developed from natural ingredients with safety as a prerequisite. It has been formulated to be used in conjunction with any Cannabinoid or Opiate pain killer to
enhance their pain modulating effects.
Another clause developed into the directive of this composition is to lower the addictive potential of any opioid drug. Thus far, the results of this process on
humans has shown to be very promising.
Meehan Formulations- Higher Compound Abstract from Patent
A composition which includes Phenylalanine, Serine, Glutamine and GABA (γ - aminobutyric acid). The composition contains the essential amino acids Phenylalanine, Glutamine; the non-essential amino acid Serine and GABA ( γ aminobutyric acid) in concentrations effective to influence or modulate the
neurotransmitter pentapeptide enkephalin. This directive incorporates pain reducing potentiality.
The use of tetrahydrocannibinol (THC) and cannabichromene (CBC; which is structurally similar to the natural cannabinoid groups) in the management of pain has been well documented. THC is a chemical which binds to the specific receptor site; cannabinoid receptor CB1 and CB2. The composition presented here is proposed to act as a allosteric modulator, alone or in conjunction with THC, of the μ and δ-opioid receptors, which is one of the biochemical destinies of THC. The inventor has recognized that THC and CBC stimulates descending biochemical pathways of antinociception, creating the analgesia effect noted and therefore presents the composition as a isolated component or in conjunction with THC, CBC or the natural cannabinoid group in enhancing this stimulatory effect which reduces pain and inflammation.
Since the understood increase in enkephalin activity and the descending pathways of antinociseption creates analgesia and diminishment in neuralgia, the present inventor has found that it would be advantageous to develop formulations which increase the allosteric modulating effect of both μ and δ -opioid receptors, increase enkephalin activity and stimulate descending pathways of antinociception.
The inventor has recognized that the reduction of pain may be enhanced in animals by utilizing the composition which contains the amino acid Phenylalanine, Serine, Glutamine and GABA in an ingestible form.
The disclosure relates to a composition which increases the activity of the naturally occurring peptide enkaphaline found in animals. Enkephalins (and beta- endorphins) are recognized as endogenous opioids. These substances are known to have potent painkilling properties.
The inventor recognizes enkephalin's role in regulating nociception, the ability for the body to interpret harmful stimuli. Enkephalins are internally propagated and bind to the body's opioid receptors. The organizational blueprint of the composition is designed to biochemically synergize each individual component to illicit a higher rate of efficacy.
Phenylalanine' role as an analgesic is best postulated by its blockage of enkephaline degradation. Phenylalanine has demonstrated to produce nalaxone reversible analgesia and consequently increase the analgesic properties of enkephalins. Penylalanine is the primary precursor for dopamine. The inventor recognizes the role of dopaminergic neurotransmission as a natural analgesic within the supraspinal regions and the role of dopamines descending inhibition of pain. Decreased levels of dopamine levels are probable for increased pain signaling in many animal conditions
Serine's role participates in the phosphorylation of serine containing analogs and has been recognized to potentiate the blood brain barrier permeability and CNS bioavailability of peptides. This process assists in the biochemical delivery platform of the composition.
Glutamine is one of the few amino acids capable of penetrating the blood brain barrier. Glutamine biosynthesizes glutamate and hence has a two fold purpose in the composition. It serves in the biosynthesis of y-aminobuturic acid. Increasing the blood brain barrier penetrating mechanism presents a higher efficacy potential for increased rates of GABA, THC and CBC within the RAIC
GABA (y-aminobutyric acid) plays a chief role in reducing neuronal excitability in the nervous system. It is synthesized from glutamate via GAD reaction. It has been demonstrated that the cerebral cortex, partakes in the role of regulating pain. The inventor recognizes that when GABA levels are increased in the small region of the cerebral cortex, the rostral angular insular cortex (RAIC), the animal(s) displayed increased and consistent analgesia. This suggests that GABA functions in part to enhance the inhibition of the neurons which illicit pain. By utilizing Glutamine/ Glutamate in conjunction with GABA, the potentiating effect on the RAIC is heightened.
t Immunopharmacol. 2016 Aug;37:59-64. doi: 10.1016/j.intimp.2016.02.015. Epub 2016 Feb 24.
Methionine enkephalin, its role in immunoregulation and cancer therapy.
Zhao D1 , Plotnikoff N2 , Griffin N2 , Song T3 , Shan F1 .
Methionine enkephalin (MENK), an endogenous neuropeptide has a crucial role in both neuroendocrine and immune systems. MENK is believed to have an immunoregulatory activity to have cancer biotherapy activity by binding to the opioid receptors on immune and cancer cells. Clinical trial studies in cancer patients have shown that MENK activates immune cells directly and by inhibiting regulatory T-cells (Tregs). MENK may also change the tumor microenvironment by binding to opioid receptor on or in cancer cells. All of these mechanisms of action have biologic significance and potential for use in cancer immunotherapy. Furthermore, they reveal a relationship between the endocrine and immune systems. Due to the apparent role of MENK in cancer therapy we reviewed herein, the research undertaken with MENK in recent years; which has advanced our understanding of the role MENK has in cancer progression and its relationship to immunity, supporting MENK as a new strategy for cancer immunotherapy. Copyright © 2016 Elsevier B.V. All rights reserved.
Cancer therapy; Immunoregulation; MENK; MENKr; Methionine enkephalin; NK cells; Treg cells